Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2512343 | 0.87 | L3MBTL1 (0.65) | LMNAMAPTL3MBTL1HTTTSHR | |
| Ethylene SCHEMBL27874359 | 0.86 | L3MBTL1 (0.64) | LMNAMAPTL3MBTL1HTTTSHR | |
| SCHEMBL10915368 | 0.86 | GAA (0.57) | LMNAMAPTL3MBTL1HTTTSHR | |
| Carbamic Acid SCHEMBL28548246 | 0.83 | L3MBTL1 (0.61) | LMNAMAPTL3MBTL1HTTTSHR | |
| SCHEMBL15630854 | 0.81 | LMNA (0.51) | LMNAMAPTL3MBTL1HTTTSHR | |
| SCHEMBL2607715 | 0.80 | HPGD (0.50) | LMNAMAPTL3MBTL1HTTMEN1 | |
| SCHEMBL2607667 | 0.80 | LMNA (0.66) | LMNAMAPTHTTTSHRMEN1 | |
| SCHEMBL2607504 | 0.80 | MAPT (0.73) | LMNAMAPTL3MBTL1TSHRMEN1 | |
| SCHEMBL6179163 | 0.79 | GAA (0.47) | LMNAMAPTL3MBTL1HTTTSHR | |
| SCHEMBL2607714 | 0.79 | CYP1A2 (0.48) | LMNAMAPTL3MBTL1HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447134-B2 | Compounds and methods for treating mammalian gastrointestinal microbial infections | BRANDEIS UNIVERSITY (US) | 2016-09-20 | — | — | US | disclosed |
| US-20150210727-A1 | COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-07-30 | — | — | US | disclosed |
| WO-2014028931-A2 | COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS | BRANDEIS UNIVERSITY (US) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210727-A1 | COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS | IMPDH1, IMPDH2, IMPA1 | LMNA 4240/4885MAPT 3597/4885L3MBTL1 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.